中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2009年
6期
608-610
,共3页
邰国梅%张军宁%王建平%王宜宗
邰國梅%張軍寧%王建平%王宜宗
태국매%장군저%왕건평%왕의종
XRCC1%单核苷酸多态%鼻咽癌%放射治疗
XRCC1%單覈苷痠多態%鼻嚥癌%放射治療
XRCC1%단핵감산다태%비인암%방사치료
XRCC1%Polymorphisms%Nasopharygeal carcinoma%Radiotherapy
目的 探讨XRCC1单核苷酸多态性与鼻咽癌放疗敏感性的关联性.方法 放疗前采鼻咽癌患者静脉血,用多聚链酶反应-高温连接酶反应(PCR-LDR)进行XRCC1Arg399GIn基因的分型,观察各型放疗中及放疗后3个月的疗效.结果 放疗中期G1n/G1n基因型的肿瘤退缩率为0.855±0.026,显著高于Are/G1n基因型的0.386±0.183和Arg/Arg基因型的0.377±0.169,差异有统计学意义(F=11.16,P=0.0003);XRCCI Codon399G1n/G1n型放疗后3个月CR达100%,Arg/G1n型为76.2%,Are,/Arg型为66.7%.三者差异无统计学意义.结论 XRCC1Codon399基因型可以预测鼻咽癌放疗中期的局部疗效.
目的 探討XRCC1單覈苷痠多態性與鼻嚥癌放療敏感性的關聯性.方法 放療前採鼻嚥癌患者靜脈血,用多聚鏈酶反應-高溫連接酶反應(PCR-LDR)進行XRCC1Arg399GIn基因的分型,觀察各型放療中及放療後3箇月的療效.結果 放療中期G1n/G1n基因型的腫瘤退縮率為0.855±0.026,顯著高于Are/G1n基因型的0.386±0.183和Arg/Arg基因型的0.377±0.169,差異有統計學意義(F=11.16,P=0.0003);XRCCI Codon399G1n/G1n型放療後3箇月CR達100%,Arg/G1n型為76.2%,Are,/Arg型為66.7%.三者差異無統計學意義.結論 XRCC1Codon399基因型可以預測鼻嚥癌放療中期的跼部療效.
목적 탐토XRCC1단핵감산다태성여비인암방료민감성적관련성.방법 방료전채비인암환자정맥혈,용다취련매반응-고온련접매반응(PCR-LDR)진행XRCC1Arg399GIn기인적분형,관찰각형방료중급방료후3개월적료효.결과 방료중기G1n/G1n기인형적종류퇴축솔위0.855±0.026,현저고우Are/G1n기인형적0.386±0.183화Arg/Arg기인형적0.377±0.169,차이유통계학의의(F=11.16,P=0.0003);XRCCI Codon399G1n/G1n형방료후3개월CR체100%,Arg/G1n형위76.2%,Are,/Arg형위66.7%.삼자차이무통계학의의.결론 XRCC1Codon399기인형가이예측비인암방료중기적국부료효.
Objective To find the intrinsic influencing factor of radiosensitivity, and to detect the polymorphisms of XRCC1 of the patients suffering from nasopharygeal carcinoma (NPC) and the different short-term curative effect of radiotherapy. Methods XRCC1 Codon Arg399Gln was determined by polymerase chain reaction and ligase detection reaction(PCR-LDR), and the effect of radiotherapy of NPC on mid-therapy and 3 months after finishing radiation were observed. Results On mid-radiotherapy, the retraction rate of Gln/Gln genotype was 0.855 ± 0.026, which was higher than that of Arg/Gln (0.386 ± 0.183) and Arg/Arg genotypes (0.377±0.169) (F = 11.16, P = 0.0003). The CR rate of 3 months after radiotherapy of the case with Gln/Gln was 100% , Arg/Gln was 76.2% , Arg/Arg was 66.7% ( P > 0.05). Conclusion Polymorphisms of XRCClArg399Gln could be a predictor for the radiotherapy effect of NPC on mid-radiotherapy.